A phase II study of lenvatinib a multi-targeted tyrosine kinase inhibitor combined with pembrolizumab (PD-1 inhibitor) for the treatment of metastatic gastroesophageal cancer patients who have progressed on first or subsequent line therapies

Brief description of study

If you have been diagnosed with gastroesophageal, stomach, or gastroesophageal junction (GEJ) cancers, you may qualify for this clinical trial. The goal of this phase II study is to determine whether combination therapy of lenvatinib ( LENVIMA®) with pembrolizumab ( KEYTRUDA®) is safe and effective in treating metastatic gastroesophageal cancer that has progressed on first or subsequent line{s) therapies. This study will also determine what effects lenvatinib and pembrolizumab has on you and your disease.


Clinical Study Identifier: s17-00626
ClinicalTrials.gov Identifier: NCT03321630
Principal Investigator: Paul E. Oberstein.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.